About the WISPer Trial

The purpose of this study is to evaluate the efficacy and safety of an investigational medicine in people living with Idiopathic Pulmonary Fibrosis (IPF).

Quick Links /
Jump to Section:

Trial Overview

Participants

Total Participants

Approximately 164 participants are expected to enroll in the trial.

Weeks

Duration

The total duration of the study is up to 32 weeks, including a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up period.

Dosing Groups

Randomized

Participants are randomized in a 1:1 ratio to receive MTX-463 or placebo.

The total duration of the study is up to 32 weeks and consists of three parts.

Learn More About the Trial

WISPer Trial Overview

Study Drug MTX-463

You may be eligible to participate if you are:

Age 40 years or older

Diagnosed with IPF within the past 7 years

Have a Forced Vital Capacity (FVC) of 45% predicted or greater

You may be eligible for this trial while using approved treatments.

Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to being enrolled in the study. Not all individuals may qualify for this study.

Find Clinical Trial Sites

Discover if there is a clinical trial site near you.

What can I expect if I join the study?

As a participant in the WISPer Trial, you will be randomly assigned to receive an infusion; this can be either the active investigational medication or placebo (the randomization ratio is 1:1). Placebo does not contain any active medication.

Participants in the clinical trial may be reimbursed for study required travel and receive study required medical care at no cost. The investigational medication will be provided at no cost to you. This investigational medication has not been approved for use by the FDA outside of this study.

Can I change my mind?

You can withdraw from the study at any time, for any reason. Even if you begin the study, you can change your mind at any point. The study doctor will discuss your care options with you if you decide to withdraw from the study.

"The medicine I'm on did not exist 10 years ago, so we have got to stay active on research. We've got to stay active in improving pharmaceuticals and treatments. Research is a huge part of that."

Matt, Living with IPF